NuPathe OK'd to market 1st FDA-approved migraine patch
This article was originally published in Clinica
Executive Summary
Right on schedule, NuPathe won US approval on 17 January for its transdermal sumatriptan migraine patch Zecuity (NP101), sending the firm's shares soaring nearly 20% in after-hours trading.